Skvortsov S V, Lytsar' B N, Samokhodskaia L M, Vasil'ev A P, Kvasovka V V, Shaĭkhaev G O
Klin Lab Diagn. 1998 Jan(1):42-4.
HBV and HCV markers were detected in the blood serum of patients with acute and chronic hepatitis B (HCV), chronic hepatis C (HCV), and acute nonA, non-B, non-C hepatitis by enzyme immunoassay and the polymerase chain reaction (PCR) in order to assess the clinical value of PCR for the diagnosis of HBV and HCV and monitor the antiviral roferon A therapy in patients with HCV. HBV DNA was detected by the PCR in 100% of acute HBV patients and in 65.7% of chronic HBV patients. In chronic HCV, the PCR detected HCV RNA in 71% of cases. After roferon A therapy, HCV RNA was no longer detected in 43.2% of PCR-positive patients. PCR is recommended for the diagnosis of acute and chronic HCV, selecting the patient groups, and assessing the efficacy of specific therapy.
采用酶免疫测定法和聚合酶链反应（PCR）检测急性和慢性乙型肝炎（丙型肝炎）、慢性丙型肝炎以及急性非甲、非乙、非丙型肝炎患者血清中的乙肝病毒（HBV）和丙肝病毒（HCV）标志物，以评估PCR在HBV和HCV诊断中的临床价值，并监测丙肝患者的抗病毒干扰素A治疗。100%的急性乙肝患者和65.7%的慢性乙肝患者通过PCR检测到HBV DNA。在慢性丙肝患者中，71%的病例通过PCR检测到HCV RNA。干扰素A治疗后，43.2%的PCR阳性患者未再检测到HCV RNA。推荐使用PCR诊断急性和慢性丙肝、选择患者群体以及评估特异性治疗的疗效。
